Kangana Ranaut's Manikarnika is not a biopic, but it has attracted the unwanted attention of Sarva Brahman Mahasabha, a Brahmin group from Rajasthan, who claims the film distorts history.
Manikarnika is based on Rani, a book authored by Jaishree Misra, which claims that the queen of Jhansi had an affair with British officer Robert Ellis.
Sarva Brahman Mahasabha president Suresh Mishra reportedly held a press conference in Jaipur to raise objections to scenes portraying love affair between Rani of Jhansi and Ellis.
He said, “We learnt about it from our friends and acquaintances in various parts of Rajasthan where some scenes of the film are being shot. The film is based on a foreigner’s book and tries to dampen the queen’s reputation.” .
“Nobody can even imagine that Maharani Laxmi Bai could have an affair. She died fighting the British at a young age. If a film is to be made on her life, it should be a biopic,” said Mishra.
Interestingly, the Rajput Karni Sena has extended their support to the group. The Sarva Brahman Mahasabha had supported the anti-Padmaavat protests staged by the Karni Sena.
Just a few days ago, the Karni Sena dropped their protests over Padmaavat, saying the film glorifies the valour of Rajputs.
Karni Sena leader Yogendra Singh Katar revealed last week that a few of its members watched the movie and found nothing objectionable in it. The movie will make Rajputs proud, he said.
The Karni Sena had been objecting to the movie’s release claiming it distorts history and portrays the Rajputs in bad light. The group was also miffed at the reported existence of a dream sequence featuring Alauddin Khilji and Rani Padmini. Padmaavat director Sanjay Leela Bhansali had always denied that such a sequence existed.
In a letter, the Karni Sena leader said the group was taking back their protest and added that they would help to release the film in Rajasthan, Madhya Pradesh and Gujarat.
In January, the Supreme Court of India lifted the ban on the movie imposed by several states and ordered them to ensure the movie was released in a peaceful manner. However, several cinema hall owners put off screening the film in the wake of protests from Karni Sena members in Gujarat and Haryana.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.